DCC and neoplasm: First preclinical studies revealed that the inhibition of netrin-1 interaction with its receptors by a decoy recombinant DCC fragment (DCC-5Fbn) led to increased tumor cell death and significant reduction of the tumor mass in a murine xenograft lung cancer model [20], [21].